• Home
  • Who We Are
    • About Us
    • From Our Chairman
    • Faculty Directory
    • Faculty Affairs
    • Newsletter Archive
  • Our Divisions
    • Cardiology
    • Endocrinology
    • Gastroenterology
    • General Internal Medicine
    • Geriatrics and Palliative Medicine
    • Hematology/Oncology
    • Infectious Diseases
    • Kidney Disease & Hypertension
    • Obstetric Medicine
    • Pulmonary, Critical Care & Sleep Medicine
    • Rheumatology
  • Fellowship Programs
    • Addiction Medicine
    • Cardiology
    • Critical Care Medicine
    • Endocrinology
    • Gastroenterology
    • Geriatrics
    • Hematology/Oncology
    • HIV Medicine
    • Hospice & Palliative Medicine
    • Infectious Diseases
    • Kidney Disease & Hypertension
    • Obstetric & Consultative Medicine
    • Pulmonary, Critical Care & Sleep Medicine
    • Rheumatology
  • Residency Programs
  • Research
  • Life in RI

Infectious Diseases – Investigators – Nau

Gerard J. Nau, MD, PhD, FIDSA

The long-term goal of the Nau laboratory is to exploit fundamental knowledge of bacterial pathogenesis and innate immunity to develop innovative therapies against infectious diseases. The host-pathogen interaction is central to our studies, with experiments devoted to both sides of that interaction. Our experimental approaches include genetics, biochemistry, RNA analysis, and various infection models.

One focus of the laboratory is to understand what makes Francisella tularensis, the causative agent of tularemia, pathogenic. A wide range of molecular tools are used to alter gene content and protein expression in a variety of Francisella strains. These experiments characterize virulence factors as well as proteins involved in normal bacterial processes that are central to the microorganism. Virulence factors that investigate include a Francisella protein that inhibits NFκB signaling and the bacterium’s secretion systems. We are also studying a family of proteins that share a common domain and that regulate the outer bacterial envelope. Potential drug targets identified in Francisella strains are also studied in other Gram-negative and Gram-positive bacteria to generalize our findings.

Another focus is to study the host’s response to infection. F. tularensis suppresses innate immune activation through a variety of mechanisms. The Nau lab has focused on inflammation, Toll-like receptor activation, cytokine responses, inhibition of NFκB, intracellular growth in immune and non-immune cells in vitro, and the virulence of bacterial strains in invertebrate and mammalian hosts. The lab also investigates host defenses and inflammation in other conditions, such as aging. Ultimately, we seek to modulate host defenses as a means to augment anti-infective therapies. The laboratory also supports the COBRE Center for Antimicrobial Resistance and Therapeutic Discovery with the Animal Models Core.

Keywords: Francisella tularensis, tularemia, innate immunity, inflammation, Toll-like receptor, NFκB, virulence, pathogenesis, aging, antibiotic resistance

Key Publications:

Talbot GH, Jezek A, Murray BE, Jones RN, Ebright RH, Nau GJ, Rodvold KA, Newland JG, Boucher HW; Infectious Diseases Society of America. Clin Infect Dis. 2019 Feb 1. [Epub ahead of print] PMID: 30715222

Jayamani E, Tharmalingam N, Rajamuthiah R, Coleman JJ, Kim W, Okoli I, Hernandez AM, Lee K, Nau GJ, Ausubel FM, Mylonakis E. Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation of Therapeutic Compounds. Antimicrob Agents Chemother. 2017 Aug 24;61(9). PMC5571314

Brown MJ, Russo BC, O’Dee DM, Schmitt DM, Nau GJ. The contribution of the glycine cleavage system to the pathogenesis of Francisella tularensis. Microbes Infect. 2014 Apr;16(4):300-9. PMC4089098.

Schmitt DM, O’Dee DM, Cowan BN, Birch JW-M, Massella LK, Nau GJ, Horzempa J. Use of resazurin as a novel antimicrobial agent against Francisella tularensis. Front Cell Infect Microbiol. 2013 Dec 6;3:93. PMC3853850

Russo BC, Brown MJ, Nau GJ. MyD88 dependent signaling prolongs survival and reduces bacterial burden during pulmonary infection with virulent Francisella tularensis. Am J Pathol. 2013 Oct;183(4):1223-32. PMC3791678

Russo BC, Horzempa J, O’Dee DM, Schmitt DM, Brown MJ, Carlson PE Jr, Xavier RJ, Nau GJ. A Francisella tularensis locus required for spermine responsiveness is necessary for virulence. Infect Immun. 2011 Sep;79(9):3665-76. PMC3165480

Horzempa J, O’Dee DM, Beer-Stolz D, Franks JM, Clay D, Nau GJ. Invasion of erythrocytes by Francisella tularensis. J Infect Dis. 2011 Jul;204(1):51-9. PMC3105038.

Carlson PE Jr, Horzempa J, O’Dee DM, Robinson CM, Neophytou P, Labrinidis A, Nau GJ. Global transcriptional response to spermine, a component of the intra-macrophage environment, reveals regulation of Francisella gene expression through insertion sequence elements. J Bacteriol. 2009 Nov;191(22):6855-64. Epub 2009 Sep 11. PMC2772466

Horzempa, J, Carlson PE Jr, O’Dee DM, Shanks RM, Nau GJ. Global transcriptional response to mammalian temperature provides new insight into Francisella tularensis pathogenesis. BMC Microbiol. 2008 Oct 8;8:172 PMC2576331

Carlson PE Jr, Carroll JA, O’Dee D, Nau GJ. Modulation of virulence factors in Francisella tularensis determines human macrophage responses. Microb Pathog. 2007 May-Jun;42(5-6):204-14. PMC2699611

Images:

Click here to view a selection of images. (PDF)

Contact Information:

Gerard J. Nau, MD, PhD, FIDSA
Rhode Island Hospital
Aldrich 722
593 Eddy St.
Providence, RI 02903
Tel: 401-444-7432
Email: gerard_nau@brown.edu

Additional links of interest:

Profile at Brown.edu

Infectious Diseases Society of America

American Society for Microbiology

Tularemia International Society

COBRE Center for Antimicrobial Resistance and Therapeutic Discovery (CARTD)

Infectious Diseases

  • Overview
  • Faculty
  • Fellowship Programs
    • Infectious Diseases Fellowship
    • HIV Medicine Fellowship
  • Research Centers
  • Investigators
  • Publications
  • Diversity, Equity and Inclusion

About Us

The Department of Medicine at Alpert Medical School is comprised of eleven distinct Divisions. These Divisions, working in conjunction with the community doctors who comprise our Primary Care offerings, provide patients with an outstanding level of care both within the Brown affiliated hospitals and throughout several community-based clinical locations. In addition to patient services, several of our Divisions offer exceptional programs for Residents and Fellows within their designated areas of expertise.

Useful Links

  • Brown Internal Medicine Residency
  • Alpert Medical School
  • Brown University
  • Rhode Island Hospital
  • The Miriam Hospital
  • Providence VA Medical Center
  • How To Reach Us

    Office of the Physician-in-Chief
    Louis B. Rice, MD
    593 Eddy Street
    Providence, RI 02903